Journal of Clinical Oncology
Articles in this Issue
Comparative analysis of demographics and outcomes in hospitalized patients with young- versus average-onset colorectal cancer in New York state (2017-2022).
27 Background: Recent studies have shown an increasing incidence of colorectal cancer (CRC) among young patients. This study investigates clinical outcome...
The importance of treatment handling and compliance on overall response rate in a phase III study of metastatic colorectal cancer: Post-hoc per protocol analyses of the AGENT trial.
205 Background: To study the compliance in handling the investigational medicinal product (IMP) and its impact on outcomes in patients with metastatic col...
Refining colorectal cancer screening strategies using polygenic risk scores and classical risk factors: A proof-of-concept study in the UK Biobank cohort.
104 Background: While the rising incidence of CRC in younger populations has led to a push for lowering the screening age to 40, current clinical guidelin...
EORTC1527/JCOG1609INT/ESSO02: Diffusion-weighted magnetic resonance imaging (DW-MRI) assessment of initially unresectable liver metastasis to improve surgical planning (DREAM)—Primary analysis.
257 Background: Disappearing liver metastases (DLMs) diagnosed on post-chemotherapy (Cx) computed tomography (CT) is a favorable prognostic factor in pati...
Analysis of tumor microenvironmental features of primary and synchronous liver metastases from patients with colorectal cancer using a deep learning algorithm.
251 Background: The development of colorectal liver metastases (CRLM) is associated with poor prognosis, and recent data suggest that metastasis to the li...
Telotristat ethyl to promote weight stability in patients with advanced pancreatic cancer.
747 Background: Cachexia a key feature of pancreatic ductal adenocarcinoma (PDAC), affects up to 80% of patients (pts), and is associated with worse outco...
The role of immunotherapy for real-world patients with HER2-negative advanced gastric cancer between 2011-2023.
404 Background: Although the appearance of immunotherapy has apparently brought benefits for all patients (pts) with advanced gastric cancer (AGC), the ma...
Updated survival results of ZL-IRIAN: Irinotecan plus anlotinib or in combination with penpulimab as second-line treatment of metastatic colorectal cancer.
167 Background: The irinotecan based chemotherapy in combination with bevacizumab had become the standard second-line treatment for metastatic colorectal...
<i>TP53</i> Y220C mutations in pancreatic ductal adenocarcinoma (PDAC): A genomic landscape study.
761 Background: A novel targeted therapy designed to restore wild-type function to the p53 Y220C mutant protein has demonstrated promising activity in an...
Patient-centered adverse event reporting in clinical trials: A novel approach using ECOG-ACRIN E2211.
658 Background: The Common Terminology Criteria for Adverse Events (CTCAE) classifies adverse events (AEs) in clinical trials but traditionally limits the...
KEYMAKER-U06: Phase 1/2 umbrella platform study of TROP2 antibody-drug conjugate sacituzumab tirumotecan plus pembrolizumab plus chemotherapy (substudy 06C) and sacituzumab tirumotecan plus paclitaxel (substudy 06D) in gastroesophageal adenocarcinoma.
TPS511 Background: Treatment options for patients with gastroesophageal adenocarcinoma (GEA) are limited and prognosis is poor. KEYMAKER-U06 is a multicen...
Increasing RAS mutation result availability in newly diagnosed patients with metastatic colorectal cancer by their first outpatient medical oncology clinic visit at a large safety net hospital.
110 Background: Rat sarcoma virus mutation testing (RASmt) is critical in guiding systemic therapy selection for patients with metastatic colorectal cance...
The effect of TU-100 on hepatocarcinogenesis and colorectal liver metastasis in MASH model.
577 Background: TU-100 is most commonly used herbal medicine in clinical setting. We have already reported that TU-100 suppressed dysbiosis (J Med Invest,...
A real-world study of treatment patterns among patients (pts) with metastatic colorectal cancer (mCRC) receiving third-line (3L) or fourth-line (4L) treatment in the US.
64 Background: There are limited real-world data describing 3L and 4L treatments for pts with mCRC. However, the landscape is evolving with new options be...
Differential gut microbiota profiles among normal colorectal mucosa, adenomatous and hyperplastic polyps in healthy volunteers: ColoMAR-1 study.
271 Background: Increasing evidence indicates that the interaction between intestinal microbiota and host cells plays an important role in colorectal canc...
Real-world use of supportive medications to prevent and manage key adverse events during first-line (1L) treatment of metastatic pancreatic adenocarcinoma (mPDAC) with FOLFIRINOX (FFX), FFX without 5FU bolus, and gemcitabine+nab-paclitaxel (GnP).
695 Background: 1L treatment of mPDAC with FFX or GnP typically requires supportive care to alleviate toxic effects. Two of the most common adverse events...
The prognostic value of HER2 gene dosage and heterogeneity at a single-cell resolution in gastroesophageal adenocarcinoma.
473 Background: HER2 gene dosage (i.e. level of amplification) and heterogeneity are key prognostic variables for HER2+ gastroesophageal adenocarcinoma (G...
First-in-human, phase 1a, dose escalation study of BGB-B167, a CEA x 4-1BB bispecific antibody, as monotherapy or combined with tislelizumab (anti-PD-1), in patients with selected advanced or metastatic solid tumors.
123 Background: BGB-B167 is potentially a first-in-class IgG-based bispecific antibody that targets CEA, a tumor-associated antigen overexpressed in many...
Molecular characteristics and prognostic impact of <i>GNAS</i> mutations in colorectal cancer: An international collaborative study between United States and Japan.
48 Background: GNAS (Guanine nucleotide-binding protein, alpha stimulating) encodes the alpha subunit of the stimulatory G protein, and gain o...
Management of patients with locally advanced rectal cancer in the total neoadjuvant therapy (TNT) era: Experience from Argentina.
85 Background: In the last years a paradigm shift has changed the way we manage non metastatic rectal cancer. The varied options within TNT have gradually...
Relationship between PD-L1 expression and the number of biopsy specimens in advanced gastric cancer.
481 Background: Programmed cell death ligand 1 (PD-L1) expression shows spatial heterogeneity in gastric cancer. Compared with single biopsies, multiple b...
Phase 1/2 study of FOG-001, a first-in-class direct β-catenin:TCF inhibitor, in patients with colorectal cancer, hepatocellular carcinoma, and other locally advanced or metastatic solid tumors.
TPS322 Background: Wnt/B-catenin pathway activation, which is frequently present in most colorectal cancers and a variety of other solid tumors, is associ...
Tumor lysis syndrome in colorectal cancer: A systematic review of clinical characteristics.
122 Background: Tumor lysis syndrome (TLS) is an oncologic emergency resulting from the release of potassium, phosphorus, and nucleic acids from tumor cel...
Effect of adjuvant radiotherapy after endoscopic resection of early esophagus cancer to prevent new intraluminal mucosal recurrence.
381 Background: Endoscopic resection (ER) is effective for treating T1a early esophageal squamous cell carcinoma (ESCC). Occasional distant metastasis and...
A multimodal deep learning approach for the prognostic stratification of patients with colorectal cancer (CRC).
287 Background: Traditional prognostic systems like the AJCC TNM staging for colorectal cancer (CRC) often fall short in predicting long-term patient outc...